$PTHS Cashflow Statement | Understand Stock

$PTHS

$14.50 -$0.70 (4.61%) Close

$PTHS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023
Cash flow from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Accretion of interest for royalty obligations
Change in fair value of convertible note
Depreciation of property and equipment
Amortization of intangible assets
Impairment of intangible assets
Issuance cost from shares issued on extension of bridge loan
Issuance cost from shares issued on extension of investor note
Lease amortization expense
Stock-based compensation
Shares issued for license
Gain on default judgement
Inventory write-off
Gain on default judgment
Changes in operating assets and liabilities:
Accounts payable and accrued expenses
Accounts receivable
Inventory
Prepaid expenses
Deferred offering costs
Operating lease right-of-use assets
Accounts payable
Accrued expenses
Due from Chromocell Corporation
Contingent consideration
Operating lease liabilities
Deferred revenue
Deferred income tax
Other assets and liabilities
Net cash used in operating activities
Cash flow from investing activities:
Purchases of property and equipment
Acquisition of LNHC, Inc.
Net cash used in investing activities
Cash flow from financing activities:
Proceeds from stock option exercises
Proceeds from convertible note
Proceeds from loan payable, net of debt discount
Proceeds from loan payable - related party, net of debt discount
Payment of bridge loan, net of debt discount
Shares issued for cash
Payment of loan payable, net of debt discount
Common stock issued for cash
Recission of common stock
Rescission of common stock
Repurchase of common stock under stock repurchase plan
Shares issued for cash under equity line of credit
Net cash provided by financing activities
Net increase in cash and cash equivalents
CASH AT BEGINNING OF YEAR
CASH AT END OF YEAR
Cash, cash equivalents and restricted cash as of beginning of period
Cash, cash equivalents and restricted cash as of end of period
Supplemental cash flow information:
Cash paid for income taxes
Cash paid for interest expense
Supplemental non-cash investing and financing activities:
Debt discount from shares issued on extension of bridge loan
Shares forfeited
Royalty obligation extinguishment
Issuance costs allocated to convertible debt
Transfer of liabilities to Chromocell Corp for Series C Preferred Stock
Accounts payable and accrued expenses converted to loans payable
Accounts payable and accrued expenses converted to loans payable - related party
Shares issued for payment of accounts payable
PIPE proceeds allocated to accounts payable
PIPE proceeds allocated to fees
Royalty agreement liability reclassified from additional paid in capital
Debt discount from common stock issued for extension of bridge loan
Shares issued for payment of accounts payable or for services
Conversion of notes to common stock
Transfer of liabilities to Chromocell Corporation for Series C Preferred Stock
Account payable and accrued expenses converted to notes
Nonrelated Party
Related Party
Shares issued for payment of accrued interest
Shares issued for payment of principal on loan payable
Cash and cash equivalents
Restricted cash

Comments